TERN - Rasio utang marang kapitalisasi buku Terns Pharma

Terns Pharmaceuticals (TERN) focuses on developing oral treatments for obesity and liver pathologies, where future profits will be based on insurance reimbursements. Currently, market levers of influence are limited, and the valuation potential is fixed at 0.00 pending the FDA verdict. The current exchange quotes on GURU.Markets visualized below complement the development picture of the company's closed therapeutic network based on unique molecules.

This indicator measures the proportion of debt relative to equity, reflecting the dependence of financial stability on asset market values and currency risks. A low debt level minimizes liquidity risk, which is critical for Terns Pharmaceuticals (TERN) when implementing joint developments in liver disease therapy, as clearly evidenced by the total debt-to-book capitalization chart.